Browse > Article
http://dx.doi.org/10.4046/trd.2011.70.1.69

A Case of Interstitial Pneumonitis and Pancytopenia Following the Combination Therapy of Pegylated Interferon and Ribavirin  

Suh, Ji-Hyun (Department of Internal Medicine, Dankook University College of Medicine)
Hahn, Sung-Hwahn (Department of Internal Medicine, Dankook University College of Medicine)
Lee, Ji-Eun (Department of Internal Medicine, Dankook University College of Medicine)
Han, Jin-Hyung (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Kyung-Mook (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Yon-Seop (Department of Internal Medicine, Dankook University College of Medicine)
Park, Jae-Suk (Department of Internal Medicine, Dankook University College of Medicine)
Jee, Young-Koo (Department of Internal Medicine, Dankook University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.70, no.1, 2011 , pp. 69-73 More about this Journal
Abstract
The combination therapy of pegylated interferon and ribavirin is the mainstay of treatment for chronic hepatitis C patients. Anti-viral therapy is commonly associated with side effects such as headache, fever, myalgia, and arthralgia. However, anti-viral therapy can continue because these side effects are mostly mild and can be improved with supportive management. Anti-viral therapy should be stopped promptly if serious side effects, such as interstitial pneumonitis or hemolytic anemia occur, although those serious side effects are rare. There were a few case reports of interferon-related interstitial pneumonitis worldwide. In Korea, one atypical case report of interstitial pneumonitis has been reported, which followed the combination therapy of interferon-alpha and ribavirin in a patient with chronic hepatitis C. We present a case of interstitial pneumonitis and pancytopenia following the combination therapy of pegylated interferon and ribavirin in a patient with chronic hepatitis C.
Keywords
Hepatitis C, Chronic; peginterferon alfa-2a; Ribavirin; Pancytopenia; Interstitial Lung Diseases;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19: 1-46.
2 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.   DOI   ScienceOn
3 Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.   DOI   ScienceOn
4 Hwang SY, Lee HJ, Park KT, Kim KY, Lee SM, Park CW, et al. Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. Korean J Gastroenterol 2007;49:166-72.
5 Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994;105:939-41.   DOI   ScienceOn
6 Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003;124:406-10.   DOI   ScienceOn
7 Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.   DOI   ScienceOn
8 Jeong HS, Oh JY, Jeon J, Seo MJ, Moon SH, Kim HS, et al. A case of interstitial pneumonitis after interferon therapy for chronic hepatitis C. Korean J Gastroenterol 1999;34:698-703.
9 Sohn BK, Sohn JH, Kim TY, Park YK, Jeon YC, Han DS. Pulmonary Toxicity by Pegylated Interferon $\alpha$-2a in a Patient with Chronic Hepatitis C. Korean J Hepatol 2007;13:103-7.
10 Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, et al. Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. Korean J Hepatol 2008;14:318-30.   DOI   ScienceOn
11 Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-26.   DOI   ScienceOn
12 Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, et al. Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection. Korean J Hepatol 2010;16:38-48.   DOI   ScienceOn
13 Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63.
14 Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994; 106:612-3.   DOI   ScienceOn